HeartBeam Secures Patent for Advanced Cardiac Monitoring in Cable-Free ECG Device
Event summary
- HeartBeam awarded new U.S. patent expanding its cable-free ECG device with acoustic sensing and fluid monitoring capabilities.
- Patent covers integration of acoustic sensors for heart valve assessment and thoracic impedance measurement for fluid detection.
- Technology aims to enable earlier identification of structural heart disease and heart failure without requiring invasive procedures.
- HeartBeam now holds 26 issued patents worldwide, reinforcing its IP position in remote cardiac care.
The big picture
HeartBeam's patent expansion positions it to address a critical gap in heart failure management—early fluid detection without invasive procedures. With nearly 6.7 million U.S. adults affected by heart failure, this technology could reduce hospitalizations and healthcare costs, aligning with broader trends toward decentralized, patient-centric cardiac care.
What we're watching
- Regulatory Pathways
- How quickly HeartBeam can secure FDA clearance for the new acoustic sensing and fluid monitoring capabilities.
- Market Adoption
- Whether physicians will integrate this multi-modal device into standard heart failure management protocols.
- Competitive Positioning
- The pace at which HeartBeam can differentiate itself from implantable and wearable cardiac monitoring solutions.